-

11:25:05 PM

AIM Stock News

AIM - AIM ImmunoTech Inc

05/15/23 8:45 AM

AMEX : AIM

earnings

AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update

– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023 – Lead clinical program, Phase 2 locally advance pancreatic cancer study, expected to enroll first patient this quarter – Phase 2 advanced recurrent ovarian

RHEA-AI

neutral

05/09/23 8:50 AM

AMEX : AIM

earnings

AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the

RHEA-AI

neutral

04/12/23 8:35 AM

AMEX : AIM

management

AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the

RHEA-AI

neutral

04/04/23 8:45 AM

AMEX : AIM

clinical trialcovid-19

AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and

RHEA-AI

positive

04/03/23 6:30 AM

AMEX : AIM

earnings

AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs – Well-positioned to achieve multiple near-term, value-driving milestones – Company to host inaugural conference call and webcast today at 8:30 AM ET OCALA, Fla., April 03, 2023

RHEA-AI

positive

03/30/23 8:45 AM

AMEX : AIM

management

AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, the

RHEA-AI

very positive

03/27/23 9:05 AM

AMEX : AIM

conferencesearnings

AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the

RHEA-AI

neutral

03/16/23 8:45 AM

AMEX : AIM

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on

RHEA-AI

neutral

03/08/23 8:45 AM

AMEX : AIM

AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the

RHEA-AI

neutral

03/06/23 8:45 AM

AMEX : AIM

AIM ImmunoTech Issues Letter to Stockholders

Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and scientific communities Poised to achieve multiple clinical and regulatory value-driving milestones in 2023

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

AIM Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websiteaimimmuno.com
CeoThomas Equels
Security nameAIM ImmunoTech Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees22
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address2117 SW Highway 484
StateFlorida
CityOcala
Zip34473-7949
CountryUS
Phone13524487797

About AIM ImmunoTech Inc

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as